» Authors » Jordyn Stuart

Jordyn Stuart

Explore the profile of Jordyn Stuart including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 487
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Heblinski M, Santiago M, Fletcher C, Stuart J, Connor M, McGregor I, et al.
Cannabis Cannabinoid Res . 2020 Dec; 5(4):305-317. PMID: 33376801
produces hundreds of bioactive compounds, including cannabinoids and terpenoids. It has been proposed that cannabinoids act in synergy with terpenoids to produce the entourage effect, a concept used to explain...
2.
Arkell T, Kevin R, Stuart J, Lintzeris N, Haber P, Ramaekers J, et al.
Drug Test Anal . 2019 Aug; 11(10):1486-1497. PMID: 31442003
Point-of-collection testing (POCT) for Δ -tetrahydrocannabinol (THC) in oral fluid is increasingly used to detect driving under the influence of cannabis (DUIC). However, previous studies have questioned the reliability and...
3.
Banister S, Olson A, Winchester M, Stuart J, Edington A, Kevin R, et al.
Drug Test Anal . 2018 Jan; PMID: 29350472
Synthetic cannabinoids are the largest and most structurally diverse class of new psychoactive substances, with manufacturers often using isomerism to evade detection and circumvent legal restriction. The regioisomeric methoxy- and...
4.
Russell J, Maguire S, Hunt G, Kesby A, Suraev A, Stuart J, et al.
Psychoneuroendocrinology . 2017 Oct; 87:83-92. PMID: 29049935
Background: Nutritional rehabilitation in anorexia nervosa (AN) is impeded by fear of food, eating and change leading to treatment resistance. Oxytocin (OT) exerts prosocial effects and modulates trust, fear, anxiety...
5.
Kevin R, Wood K, Stuart J, Mitchell A, Moir M, Banister S, et al.
J Psychopharmacol . 2017 Jan; 31(6):757-769. PMID: 28093016
Synthetic cannabinoids (SCs) have rapidly proliferated as recreational drugs, and may present a substantial health risk to vulnerable populations. However, information on possible effects of long-term use is sparse. This...
6.
Soethoudt M, Grether U, Fingerle J, Grim T, Fezza F, De Petrocellis L, et al.
Nat Commun . 2017 Jan; 8:13958. PMID: 28045021
The cannabinoid CB receptor (CBR) represents a promising therapeutic target for various forms of tissue injury and inflammatory diseases. Although numerous compounds have been developed and widely used to target...
7.
Clarke D, Stuart J, McGregor I, Arnold J
Prog Neuropsychopharmacol Biol Psychiatry . 2016 Aug; 72:9-15. PMID: 27521758
The endocannabinoid system is dysregulated in schizophrenia. Mice with heterozygous deletion of neuregulin 1 (Nrg1 HET mice) provide a well-characterised animal model of schizophrenia, and display enhanced sensitivity to stress...
8.
Banister S, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al.
ACS Chem Neurosci . 2016 Jul; 7(9):1241-54. PMID: 27421060
Indole and indazole synthetic cannabinoids (SCs) featuring l-valinate or l-tert-leucinate pendant group have recently emerged as prevalent recreational drugs, and their use has been associated with serious adverse health effects....
9.
Brzozowska N, Li K, Wang X, Booth J, Stuart J, McGregor I, et al.
PeerJ . 2016 Jun; 4:e2081. PMID: 27257556
Cannabidiol (CBD) is currently being investigated as a novel therapeutic for the treatment of CNS disorders like schizophrenia and epilepsy. ABC transporters such as P-glycoprotein (P-gp) and breast cancer resistance...
10.
Redmond W, Cawston E, Grimsey N, Stuart J, Edington A, Glass M, et al.
Br J Pharmacol . 2015 Sep; 173(1):115-27. PMID: 26398720
Background And Purpose: N-arachidonyl dopamine (NADA) has been identified as a putative endocannabinoid, but there is little information about which signalling pathways it activates. The purpose of this study was...